- Home
- TYRA
as 07-26-2024 4:00pm EST
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 896.9M | IPO Year: | 2021 |
| Target Price: | $26.33 | AVG Volume (30 days): | 179.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.38 - $22.20 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Tyra Biosciences Inc. (TYRA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bensen Daniel | TYRA | Chief Operating Officer | Jun 7 '24 | Sell | $20.00 | 200 | $4,000.00 | 431,483 | SEC Form 4 |
| Bensen Daniel | TYRA | Chief Operating Officer | Jun 7 '24 | Sell | $20.00 | 3,502 | $70,044.90 | 427,981 | SEC Form 4 |
| Bensen Daniel | TYRA | Chief Operating Officer | Mar 11 '24 | Sell | $20.00 | 200 | $4,000.00 | 431,683 | SEC Form 4 |
| Bensen Daniel | TYRA | Chief Operating Officer | Mar 6 '24 | Sell | $20.09 | 1,733 | $34,819.44 | 431,951 | SEC Form 4 |
| Bensen Daniel | TYRA | Chief Operating Officer | Mar 6 '24 | Sell | $20.00 | 68 | $1,360.00 | 431,883 | SEC Form 4 |
| Bensen Daniel | TYRA | Chief Operating Officer | Mar 1 '24 | Sell | $20.04 | 2,900 | $58,111.94 | 439,936 | SEC Form 4 |
| Bensen Daniel | TYRA | Chief Operating Officer | Mar 1 '24 | Sell | $20.08 | 5,063 | $101,653.90 | 434,873 | SEC Form 4 |
| Bensen Daniel | TYRA | Chief Operating Officer | Mar 1 '24 | Sell | $20.02 | 1,189 | $23,802.47 | 433,684 | SEC Form 4 |
| Bensen Daniel | TYRA | Chief Operating Officer | Feb 27 '24 | Sell | $20.00 | 2,050 | $41,003.28 | 442,836 | SEC Form 4 |
| Bensen Daniel | TYRA | Chief Operating Officer | Feb 27 '24 | Sell | $20.13 | 5,849 | $117,728.67 | 444,886 | SEC Form 4 |
| Bensen Daniel | TYRA | Chief Operating Officer | Feb 27 '24 | Sell | $20.00 | 745 | $14,900.00 | 450,735 | SEC Form 4 |
| Bensen Daniel | TYRA | Chief Operating Officer | Feb 12 '24 | Sell | $20.00 | 1,501 | $30,020.00 | 451,480 | SEC Form 4 |
| Bensen Daniel | TYRA | Chief Operating Officer | Feb 7 '24 | Sell | $18.09 | 9,587 | $173,466.22 | 452,981 | SEC Form 4 |
| Harris Todd | TYRA | President and CEO | Feb 2 '24 | Sell | $16.45 | 78,996 | $1,299,160.32 | 1,523,701 | SEC Form 4 |
| Harris Todd | TYRA | President and CEO | Feb 2 '24 | Sell | $17.04 | 7,187 | $122,494.51 | 1,516,514 | SEC Form 4 |
| Harris Todd | TYRA | President and CEO | Feb 2 '24 | Sell | $16.97 | 13,817 | $234,430.28 | 1,502,697 | SEC Form 4 |
| Bensen Daniel | TYRA | Chief Operating Officer | Feb 2 '24 | Sell | $16.31 | 73,093 | $1,191,898.31 | 480,281 | SEC Form 4 |
| Bensen Daniel | TYRA | Chief Operating Officer | Feb 2 '24 | Sell | $17.04 | 2,300 | $39,198.90 | 477,981 | SEC Form 4 |
| Bensen Daniel | TYRA | Chief Operating Officer | Feb 2 '24 | Sell | $18.09 | 15,413 | $278,827.34 | 462,568 | SEC Form 4 |
Latest Tyra Biosciences Inc. News
TYRA Breaking Stock News: Dive into TYRA Ticker-Specific Updates for Smart Investing
MT Newswires
24 days ago
Tyra Biosciences Plans to Develop Potential Treatment of Dwarfism, File Application in H2
PR Newswire
24 days ago
Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)
Simply Wall St.
a month ago
Does This Valuation Of Tyra Biosciences, Inc. (NASDAQ:TYRA) Imply Investors Are Overpaying?
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Simply Wall St.
2 months ago
Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
Reuters
2 months ago
Japan's service sector mood hits nearly 2-year low in May
Compare TYRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TYRA Tyra Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.